Business
ADIA Nutrition Submits Patent-Pending Autism Protocol for Independent IRB Review - Clinical Study Launch Nears
Winter Park, Florida--(Newsfile Corp. - November 24, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) announced today that, following the independent Institutional Review Board's (IRB) acceptance of its initial draft protocol and invitation to submit a final version, the company has now officially delivered the complete, Patent-Pending regenerative protocol for pediatric Autism Spectrum Disorder (ASD) for full review and potential acceptance of oversight.This submission represents a pivotal milestone.
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - November 24, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) announced today that, following the independent Institutional Review Board's (IRB) acceptance of its initial draft protocol and invitation to submit a final version, the company has now officially delivered the complete, Patent-Pending regenerative protocol for pediatric Autism Spectrum Disorder (ASD) for full review and potential acceptance of oversight.","length":457,"tagName":"p"},{"type":"text","content":"This submission represents a pivotal milestone. The full protocol, including detailed methodology, rigorous safety measures, dosing regimen, and clinical endpoints, is now under expert evaluation. IRB acceptance would immediately authorize ADIA's first-ever IRB-approved human study using antioxidants and stem cells in children with ASD.","length":342,"tagName":"p"},{"type":"text","content":""We just pressed the button on something that could be truly game-changing," said Larry Powalisz, CEO of ADIA Nutrition. "The IRB now has everything they need to green-light our work. Acceptance would open the floodgates to many more IRBs and fast-track credible, life-changing data for families, and explosive value for shareholders."","length":355,"tagName":"p"},{"type":"text","content":"Shareholders will receive prompt updates throughout the process, with the next announcement expected to be significantly larger upon IRB determination.","length":151,"tagName":"p"},{"type":"text","content":"The protocol remains confidential while intellectual property and clinical pathways advance in parallel.","length":104,"tagName":"p"},{"type":"text","content":"For questions, inquiries, or additional information, please contact Larry Powalisz at [email protected] or by phone at 321-788-0850.","length":130,"tagName":"p"},{"type":"text","content":"Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.","length":317,"tagName":"p"},{"type":"text","content":"About ADIA Nutrition Inc.:Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company a...